Cargando…

PB2016: HIGH SERUM FERRITIN LEVELS AT DIAGNOSIS PREDICT WORSE PROGNOSIS IN ADVANCED MDS IN CHILDREN.

Detalles Bibliográficos
Autores principales:	Liu, Chenmeng, Yang, Wenyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430250/ http://dx.doi.org/10.1097/01.HS9.0000974876.06000.f2

Ejemplares similares

PB1999: TOBACCO SMOKING IN MDS PATIENTS – ANALYSIS FROM THE MDS PALG REGISTRY
por: Machowicz, Rafal, et al.
Publicado: (2023)

PB2006: MOLECULAR CLINICAL CHARACTERISTICS AND PROGNOSIS OF MDS PATIENTS WITH RUNX1 MUTATION
por: Huang, Nanfang, et al.
Publicado: (2023)

PB2023: THE LEVEL OF VASCULAR ENDOTHELIAL FACTOR (VEGF) IN THE BLOOD SERUM OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS RAEB I).
por: Стародуб, Галина, et al.
Publicado: (2023)

PB2190: COMORBIDITIES PREDICT WORSE PROGNOSIS IN PATIENTS WITH POLYCYTHEMIA VERA
por: Arsenović, Isidora, et al.
Publicado: (2023)

PB2002: ASSOCIATION OF GENE MUTATIONS AND CLINICAL MANIFESTATIONS AND PROGNOSIS IN THE CLINICAL COHORT WITH 218 MDS PATIENTS
por: Wang, Xue’e, et al.
Publicado: (2023)

PB2564: COVID-19 AND FERRITIN
por: Kuiavovych, Bohdana, et al.
Publicado: (2023)

PB2204: HIGH SERUM FERRITIN AT INITIAL DIAGNOSIS IS A PREDICTOR OF BONE MARROW FIBROSIS IN PH NEGATIVE CHRONIC MYELOPROLIFERATIVE NEOPLASMS
por: Leone, Aldo, et al.
Publicado: (2023)

PB1793: NEUTROPHIL TO LYMPHOCYTE RATIO AS A PROGNOSTIC FACTOR IN AML AND MDS
por: Van Oorschot, V., et al.
Publicado: (2022)

PB2032: FACTORS ASSOCIATED WITH TRANSFUSION INDEPENDENCY POST TREATMENT IN HIGH RISK MDS PATIENTS
por: Fatima, Naveena, et al.
Publicado: (2023)

PB1989: STUDY ON THE RELATIONSHIP BETWEEN MDS AND ABNORMAL LIPID METABOLISM IN BONE MARROW MICROENVIRONMENT
por: LI, Yuchun, et al.
Publicado: (2023)

PB2060: THE MDS-SPECIFIC COMORBIDITY INDEX (MDS-CI) PREDICTS SURVIVAL INDEPENDENTLY FROM DIPSS AND MIPSS70 IN PATIENTS WITH OVERT MYELOFIBROSIS NOT ELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION.
por: Koster, K.-L., et al.
Publicado: (2022)

PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)
por: DeZern, A., et al.
Publicado: (2022)

PB2670: EQOL-MDS TRIAL: PATIENT-REPORTED OUTCOMES IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES WITH SEVERE THROMBOCYTOPENIA.
por: Oliva, Esther, et al.
Publicado: (2023)

PB2170: HIGH EXPRESSION OF AP2M1 CORRELATES WITH WORSE PROGNOSIS BY REGULATING IMMUNE MICROENVIRONMENT AND DRUG RESPONSE TO R-CHOP IN DLBCL
por: Liu, X.-D., et al.
Publicado: (2022)

PB1991: NEW MONOCYTE HEMATOLOGICAL PARAMETERS AS AN IMPORTANT INDICATOR OF MDS PATIENTS WITH POSITIVE OGATA SCORE - A PRELIMINARY STUDY
por: Dudzik, Alicja, et al.
Publicado: (2023)

PB1922: EFFECTIVENESS OF AZACITIDINE IN FRONTLINE HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS): A RETROSPECTIVE COHORT STUDY OF 382 PATIENTS
por: Rajakumaraswamy, N., et al.
Publicado: (2022)

PB1925: VENETOCLAX IN COMBINATION WITH AZACITIDINE OR LOW-DOSE CYTARABINE IN PATIENTS WITH HIGH-RISK MDS AND AML - EXPERIENCE OF A CZECH HAEMATOLOGY CENTRE.
por: Minarik, L., et al.
Publicado: (2022)

PB1919: S100A9 DEFICIENCY ACCELERATES MDS ASSOCIATED TUMOR ESCAPE VIA PD-1/PD-L1 OVEREXPRESSION
por: Wang, R., et al.
Publicado: (2022)

PB1765: DIFFERENTIAL GENE EXPRESSION PROFILE IN DNA DAMAGE SIGNALING PATHWAYS, IN DE NOVO ACUTE MYELOID LEUKEMIA AND LOW-RISK MDS PATIENTS
por: Bouchla, Anthi, et al.
Publicado: (2023)

PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY
por: de Botton, Stéphane, et al.
Publicado: (2023)

PB1926: REAL-WORLD ERYTHROPOIESIS-STIMULATING AGENT (ESA) TREATMENT PATTERNS AND OUTCOMES AMONG US PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS)
por: Mukherjee, S., et al.
Publicado: (2022)

PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
por: Zeidan, Amer M., et al.
Publicado: (2023)

PB2003: REAL-WORLD TREATMENT PATTERNS OF PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) IN A US REAL-WORLD EVIDENCE DATABASE (COTA)
por: Komrokji, Rami S., et al.
Publicado: (2023)

PB2396: HDACI COMBINED WITH LB100 PROMOTES THE OCCURRENCE OF FERROZOSIS IN CTCL
por: Shi, Wenyu
Publicado: (2023)

PB2175: NEXT-GENERATION SEQUENCING IN THE DIAGNOSIS, PROGNOSIS AND FEATURES OF THE COURSE OF THE DISEASE IN PATIENTS WITH PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Kirienko, Anna, et al.
Publicado: (2023)

PB1730: PROGNOSTIC VALUE OF EARLY T-ALL IMMUNOPHENOTYPES IN ADULTS ON THE RALL-2016 PROTOCOL
por: Vasileva, Anastasia, et al.
Publicado: (2023)

PB2116: CLINICAL PRESENTATION AND TREATMENT OUTCOME OF CHILDREN WITH B-CELL LYMPHOMA; 3-YEAR STUDY AT CHILDREN’S WELFARE TEACHING HOSPITAL (2016-2018)
por: Ghali, H., et al.
Publicado: (2022)

PB2124: MYC EXPRESSION ANALYSIS AND PROGNOSIS VALUE IN TRANSFORMED FOLLICULAR LYMPHOMA
por: Liang, J., et al.
Publicado: (2022)

PB2367: CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH NODAL PERIPHERAL T-CELL LYMPHOMA
por: Yahia, Noura Ben, et al.
Publicado: (2023)

PB1847: A PHASE 1 STUDY TO INVESTIGATE CLN-049, A FLT3/CD3 BISPECIFIC T CELL ENGAGER, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)
por: Abdul-Hay, Maher, et al.
Publicado: (2023)

PB1931: LOW SERUM CHOLESTEROL LEVEL AS A SIGNIFICANT PROGNOSTIC FACTOR IMPROVES CLL-IPI IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Gao, Rui, et al.
Publicado: (2023)

PB2372: PP2A INHIBITOR LB100 ENHANCES THE SENSITIVITY OF NPM-ALK+ALCL TO CRIZOTINIB AND REVERSES THE RESISTANCE OF ALCL TO CRIZOTINIB
por: Shi, Wenyu
Publicado: (2023)

PB2375: PLTP REGULATES BCR SIGNALING AND TUMOR MICROENVIRONMENT IN DIFFUSE LARGE B-CELL LYMPHOMA THROUGH REPROGRAMMING OF LIPID METABOLISM ENVIRONMENT
por: Shi, Wenyu
Publicado: (2023)

PB2287: END OF LIFE TRANSFUSIONS IN PATIENTS WITH AN ONCOLOGICAL DIAGNOSIS
por: Duque, L., et al.
Publicado: (2022)

PB2015: DIAGNOSIS, CLASSIFICATION AND STRATIFICATION OF MYELODYSPLASTIC SYNDROMES IN ALGERIA
por: Moussa, Yamina Bouchakour, et al.
Publicado: (2023)

PB2080: LOW DUP1 EXPRESSION PREDICTS POOR PROGNOSIS IN MULTIPLE MYELOMA
por: Lu, Jinfeng, et al.
Publicado: (2023)

PB1770: CHARACTERIZATION OF THE MUTATIONAL PROFILE OF PATIENTS WITH CBF-AML - HETEROGENEITY AND IMPACT ON THE PROGNOSIS
por: Motyko, Ekaterina, et al.
Publicado: (2023)

PB1841: NUCLEOLIN INTERACTS WITH NUCLEOPHOSMIN AS A PREDICTOR OF PROGNOSIS IN ACUTE MYELOBLASTIC LEUKEMIA
por: Pereira, Marta, et al.
Publicado: (2023)

PB2381: EFFICACY ANALYSIS OF BRUTON’S TYROSINE KINASE INHIBITOR COMBINED REGIMEN IN THE TREATMENT OF ELDERLY PATIENTS WITH RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
por: Shi, Wenyu
Publicado: (2023)

PB2086: SIMULTANEOUS DIAGNOSIS OF MULTIPLE MYELOMA AND MYELODYSPLASIA: CASE REPORT.
por: Benabed, Khaled, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j2bj4ce3df59emi8vcek8ook1a